629 related articles for article (PubMed ID: 15588348)
21. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
22. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
23. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
24. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
[TBL] [Abstract][Full Text] [Related]
26. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
27. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.
Vinner L; Wee EG; Patel S; Corbet S; Gao GP; Nielsen C; Wilson JM; Ertl HCJ; Hanke T; Fomsgaard A
J Gen Virol; 2003 Jan; 84(Pt 1):203-213. PubMed ID: 12533717
[TBL] [Abstract][Full Text] [Related]
30. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
Richmond JF; Lu S; Santoro JC; Weng J; Hu SL; Montefiori DC; Robinson HL
J Virol; 1998 Nov; 72(11):9092-100. PubMed ID: 9765454
[TBL] [Abstract][Full Text] [Related]
31. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
32. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.
Chen H; Xu X; Lin HH; Chen SH; Forsman A; Aasa-Chapman M; Jones IM
J Gen Virol; 2008 Oct; 89(Pt 10):2597-2604. PubMed ID: 18796729
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.
Shata MT; Hone DM
J Virol; 2001 Oct; 75(20):9665-70. PubMed ID: 11559798
[TBL] [Abstract][Full Text] [Related]
34. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
[TBL] [Abstract][Full Text] [Related]
35. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Beddows S; Franti M; Dey AK; Kirschner M; Iyer SP; Fisch DC; Ketas T; Yuste E; Desrosiers RC; Klasse PJ; Maddon PJ; Olson WC; Moore JP
Virology; 2007 Apr; 360(2):329-40. PubMed ID: 17126869
[TBL] [Abstract][Full Text] [Related]
36. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
[TBL] [Abstract][Full Text] [Related]
37. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
38. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.
Zolla-Pazner S; Kong XP; Jiang X; Cardozo T; Nádas A; Cohen S; Totrov M; Seaman MS; Wang S; Lu S
J Virol; 2011 Oct; 85(19):9887-98. PubMed ID: 21795338
[TBL] [Abstract][Full Text] [Related]
39. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
[TBL] [Abstract][Full Text] [Related]
40. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
Wang S; Arthos J; Lawrence JM; Van Ryk D; Mboudjeka I; Shen S; Chou TH; Montefiori DC; Lu S
J Virol; 2005 Jun; 79(12):7933-7. PubMed ID: 15919951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
